![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ARV-471 (vepdegestrant) is an investigational PROTAC protein degrader designed to target and degrade the estrogen receptor. It is being evaluated for the treatment of ER+/HER2- breast cancer.
Lead Product(s): Vepdegestrant,Palbociclib
Therapeutic Area: Oncology Product Name: ARV-471
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2024
Details:
Under the agreement, Novartis obtains worldwide development and commercialization rights of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer and also its preclinical AR-V7 program.
Lead Product(s): Luxdegalutamide,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: ARV-766
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $1,160.0 million Upfront Cash: $150.0 million
Deal Type: Licensing Agreement April 11, 2024
Details:
ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target LRRK2. It is being evaluated for the treatment of parkinson’s disease and progressive supranuclear palsy.
Lead Product(s): ARV-102
Therapeutic Area: Neurology Product Name: ARV-102
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
ARV-471 (vepdegestrant) is an investigational, orally bioavailable PROTAC protein degrader designed to specifically target and degrade the estrogen receptor. It is being evaluated in phase 3 clinical trials for the treatment of patients with ER+/HER2- breast cancer.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Product Name: ARV-471
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2024
Details:
Arvinas expects to use net proceeds to advance its clinical development programs and preclinical pipeline, including ARV-471 (vepdegestrant), an investigational orally bioavailable PROTAC® protein degrader.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Product Name: ARV-471
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 27, 2023
Details:
ARV-471 (vepdegestrant) is an investigational, orally bioavailable PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor for the treatment of patients with early and locally advanced breast cancer.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Product Name: ARV-471
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
The collaboration aims to evaluate the novel combination of CT7001 (samuraciclib), an oral, first-in-class inhibitor of CDK7, and Arvinas’ ARV-471 (vepdegestrant), an investigational oral PROTAC® estrogen receptor protein degrader being developed in metastatic breast cancer.
Lead Product(s): Samuraciclib,Fulvestrant
Therapeutic Area: Oncology Product Name: CT7001
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Carrick Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 06, 2023
Details:
ARV-766 is an investigational orally bioavailable PROTAC® protein degrader designed to degrade all clinically relevant resistance-driving point mutations of the androgen receptor (AR) and which being investigated forLate-line mCRPC.
Lead Product(s): Luxdegalutamide
Therapeutic Area: Oncology Product Name: ARV-766
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Details:
ARV-471 is an investigational, orally-bioavailable PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Lead Product(s): ARV-471,Palbociclib
Therapeutic Area: Oncology Product Name: ARV-471
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Details:
Initial goal of collaboration is to develop FoundationOne® liquid CDx as a companion diagnostic for Bavdegalutamide (ARV-110), Arvinas’ investigational Androgen receptor-targeting PROTAC® protein degrader.
Lead Product(s): Bavdegalutamide
Therapeutic Area: Oncology Product Name: ARV-110
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Foundation Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 05, 2022